Thromb Haemost 2018; 118(01): 072-081
DOI: 10.1160/TH17-02-0095
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban

Chih-Cheng Hsu
,
Pai-Feng Hsu
,
Shih-Hsien Sung
,
Shih-Te Tu
,
Ben-Hui Yu
,
Chi-Jung Huang
,
Hao-Min Cheng
Further Information

Publication History

10 February 2017

28 September 2017

Publication Date:
05 January 2018 (online)

Abstract

Background The prevalence of diabetes is growing, and diabetes is an independent risk factor for both atrial fibrillation (AF) and stroke. However, the relative effectiveness and safety of different oral anticoagulants for diabetic patients with non-valvular AF remain unclear. We aimed to compare thromboembolic events, bleeding and mortality in diabetic AF patients treated with rivaroxaban, dabigatran and warfarin.

Methods and Results Diabetic AF patients taking dabigatran (n = 322), rivaroxaban (n = 320) or warfarin (n = 1,899) were identified from the nationwide diabetes pay-for-performance program (n = 814,465) in Taiwan. Outcomes and comorbidities were evaluated by linking with Taiwan National Health Insurance Research Database. Propensity score weighting method was used to balance covariates across study groups. Patients were followed up until the first occurrence of any study outcome or the study end date. Compared with warfarin, dabigatran significantly decreased the risk of all-cause mortality (hazard ratio [HR] = 0.348, 95% confidence interval [CI] = 0.157–0.771) and gastrointestinal bleeding (HR = 0.558, 95% CI = 0.327–0.955). Relative effectiveness and safety outcomes between rivaroxaban and warfarin were comparable. Compared with rivaroxaban, dabigatran significantly decreased the risk of all-cause mortality (HR = 0.310, 95% CI = 0.121–0.798) and was associated with a borderline reduced risk for composite safety end points (HR = 0.670, 95% CI = 0.421–1.067).

Conclusion In diabetic AF patients, dabigatran and rivaroxaban showed a superior or non-inferior effectiveness and safety profile compared with warfarin. Dabigatran was associated with a significantly lower risk of mortality than rivaroxaban.

Authors' Contributions

C.-C. H. and H.-M. C. conducted study design, wrote the manuscript and interpreted data. P.-F. H. and S.-H. S. reviewed/edited the manuscript. S.-T. T. and B.-H. Y. analysed data and revised the manuscript. All authors read and approved the final manuscript.


Funding

The study was supported by Ministry of Health and Welfare, Taiwan grant (MOHW-104-TDU-B-211–113003, MOHW-105-TDU-B-211–133017, 05D9-PHBHP01, and MOHW-106-TDU-B-211-113001).


Supplementary Material

 
  • References

  • 1 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27 (05) 1047-1053
  • 2 Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103 (02) 137-149
  • 3 Xu Y, Wang L, He J. , et al; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA 2013; 310 (09) 948-959
  • 4 Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271 (11) 840-844
  • 5 Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005; 105 (03) 315-318
  • 6 Allan V, Honarbakhsh S, Casas JP. , et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost 2017; 117 (05) 837-850
  • 7 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69 (06) 546-554
  • 8 Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke?. Am J Epidemiol 1988; 128 (01) 116-123
  • 9 Guo Y, Wang H, Tian Y, Wang Y, Lip GY. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost 2016; 115 (01) 184-192
  • 10 Du X, Ninomiya T, de Galan B. , et al; ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009; 30 (09) 1128-1135
  • 11 Camm AJ, Kirchhof P, Lip GY. , et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19) 2369-2429
  • 12 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
  • 13 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
  • 14 Connolly SJ, Eikelboom J, Joyner C. , et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
  • 15 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
  • 16 Hsieh HM, Gu SM, Shin SJ, Kao HY, Lin YC, Chiu HC. Cost-effectiveness of a diabetes pay-for-performance program in diabetes patients with multiple chronic conditions. PLoS One 2015; 10 (07) e0133163
  • 17 Hsieh HM, Lin TH, Lee IC, Huang CJ, Shin SJ, Chiu HC. The association between participation in a pay-for-performance program and macrovascular complications in patients with type 2 diabetes in Taiwan: A nationwide population-based cohort study. Prev Med 2016; 85: 53-59
  • 18 Chen CC, Tseng CH, Cheng SH. Continuity of care, medication adherence, and health care outcomes among patients with newly diagnosed type 2 diabetes: a longitudinal analysis. Med Care 2013; 51 (03) 231-237
  • 19 Health and Welfare Data Science Center in Ministry of Health and Welfare [Internet]. Available from: http://www.mohw.gov.tw/CHT/DOS/DM1.aspx?f_list_no=812
  • 20 Iezzoni LI. Risk Adjustment for Measuring Healthcare Outcomes. Chicago, IL: Health Administration Press; 1997
  • 21 Bansilal S, Bloomgarden Z, Halperin JL. , et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J 2015; 170 (04) 675-682.e8
  • 22 Brambatti M, Darius H, Oldgren J. , et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol 2015; 196: 127-131
  • 23 Lip GY, Keshishian A, Kamble S. , et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 2016; 116 (05) 975-986
  • 24 Hecker J, Marten S, Keller L. , et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016; 115 (05) 939-949
  • 25 Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114 (06) 1277-1289
  • 26 Villines TC, Schnee J, Fraeman K. , et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114 (06) 1290-1298
  • 27 Avgil-Tsadok M, Jackevicius CA, Essebag V. , et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 2016; 115 (01) 152-160
  • 28 Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016; 116 (04) 754-763
  • 29 Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke 2017; 48 (04) 970-976
  • 30 Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995; 38 (09) 1061-1068
  • 31 Klem I, Wehinger C, Schneider B, Hartl E, Finsterer J, Stöllberger C. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev 2003; 19 (04) 320-328
  • 32 Wang TD, Chen WJ, Su SS. , et al. Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism. J Cardiovasc Electrophysiol 2001; 12 (08) 877-884
  • 33 Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108 (03) 476-484
  • 34 Chan YH, Kuo CT, Yeh YH. , et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol 2016; 68 (13) 1389-1401
  • 35 Graham DJ, Reichman ME, Wernecke M. , et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176 (11) 1662-1671
  • 36 Camm AJ, Lip GY, De Caterina R. , et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747
  • 37 Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2017; 117 (02) 209-218
  • 38 Yao X, Abraham NS, Alexander GC. , et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016; 5 (02) e003074
  • 39 Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015; 13 (04) 495-504
  • 40 Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016; 115 (01) 31-39
  • 41 Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis. PLoS One 2015; 10 (09) e0137444
  • 42 Chiang CE, Wu TJ, Ueng KC. , et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc 2016; 115 (11) 893-952
  • 43 Wallentin L, Yusuf S, Ezekowitz MD. , et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376 (9745): 975-983
  • 44 Ho CW, Ho MH, Chan PH. , et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46 (01) 23-30